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Certain individuals with combined deficiencies of vi-
tamin K-dependent proteins have a mutation, L394R, in
their -glutamyl carboxylase causing impaired gluta-
mate binding. The sequence surrounding Leu394 is sim-
ilar in all known carboxylases, suggesting that the re-
gion is functionally important. To test this hypothesis
we made the following mutant enzymes: W390A, Y395A,
S398A, W399A, and H404A. We purified the enzymes and
corrected the activity measurements for active enzyme
concentration. Carboxylases W390A, S398A, and H404A
had activities similar to that of wild type; however,
Y395A and W399A had lower activities than did wild
type. In the following descriptions we include our pre-
viously reported results for L394R. Kinetic studies with
the substrate FLEEL, revealed Km values of 0.5 (wild
type), 6.5 (L394R), 15 (Y395A), and 24 (W399A) mM. The
kcat values relative to wild type were 51% (L394R), 1%
(Y395A), and 2% (W399A). The kcat/Km values were 24-fold
(L394R) and >2000-fold lower for Y395A and W399A than
for wild-type carboxylase. Inhibition of FLEEL carbox-
ylation by the competitive inhibitor, Boc-mEEV, gave Ki
values of 0.013 (wild type), 1.4 (L394R), 2.1 (Y395A), and
>5 (W399A) mM. The Y395A propeptide affinity was sim-
ilar to that of wild type, but those of L394R and W399A
were 16–22-fold less than that of wild type. Results of
kinetic studies with a propeptide-containing substrate
were consistent with results of propeptide binding and
FLEEL kinetics. Although propeptide and vitamin K
binding in some mutants were affected, our data pro-
vide compelling evidence that glutamate recognition is
the primary function of the conserved region around
Leu394.
Vitamin K-dependent carboxylase, or -glutamyl carboxyl-
ase, is an integral membrane protein residing in the rough
endoplasmic reticulum. It catalyzes the post-translational
modification of specific glutamic acid residues to -carboxyglu-
tamic acid (Gla),1 a modification necessary for the activity of
certain proteins involved in blood coagulation (1), bone metab-
olism (2), and cell proliferation (3). Four other Gla protein
sequences of unknown function have also been identified (4, 5).
In addition to the glutamate substrate, -carboxylation re-
quires carbon dioxide, oxygen, and KH2, the reduced form of
vitamin K as co-substrates (6). Precursors of the physiological
substrates of carboxylase contain a propeptide sequence, which
anchors the substrate to the enzyme while multiple Glu resi-
dues are carboxylated. The conversion of glutamic acid to Gla is
coupled with the oxygenation of KH2 to vitamin K 2,3-epoxide
and has been referred to as vitamin K epoxidase activity (7, 8).
Two natural mutants of -glutamyl carboxylase have been
identified to date: L394R (9) and W501S (10). Individuals with
either mutation have bleeding disorders, due to reduced activ-
ities of all clotting factors, which are presumably only partially
carboxylated, since they have impaired calcium binding prop-
erties (11). In a subsequent characterization of recombinant
L394R carboxylase we showed that the presumed undercar-
boxylation is primarily due to a defect in glutamate-substrate
binding (12).
Comparison of the known carboxylase sequences among dif-
ferent species shows that leucine 394 is located in a highly
conserved region in the molecule (Fig. 1), between residues 374
and 405 of the human sequence (13, 14). The region between
residues 393 and 404 is totally conserved not only among the
known vertebrate carboxylase sequences but also in the known
invertebrate sequences of Drosophila, Anopheles,2 and Conus
(13–16).
In this study, we have expressed and examined the proper-
ties of mutants of some residues in this highly conserved region
of carboxylase. Our results show that the primary defect in
Y395A, W399A, and L394R is impaired binding of the gluta-
mate substrate. In addition, residues Leu394 and Trp399 appear
to be involved in linkage between the glutamate binding active
site and the propeptide binding site of carboxylase.
EXPERIMENTAL PROCEDURES
Materials—FLEEL was purchased from Bachem (Philadelphia, PA).
FIXproGla, a 59-residue recombinant peptide whose sequence is de-
rived from the propeptide and the first 41 residues of the Gla domain of
human factor IX, was prepared and purified as described (17). The
peptide ProFIX19, was synthesized by Dr. Frank Church (University of
North Carolina at Chapel Hill). The peptide Boc-mEEV was synthe-
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sized as described (18). Unlabeled and fluorescently labeled (with 5(6)-
carboxyfluorescein at the amino terminus) peptides of the human factor
IX propeptide, ProFIX18, and the consensus sequence, pCon (19), were
synthesized by Chiron Mimotopes (Clayton, Victoria, Australia). Vita-
min K1 was from Abbott Laboratories (Chicago, IL). NaH
14CO3 (specific
activity, 54 mCi/mmol) was from ICN Pharmaceuticals (Costa Mesa,
CA). L--Phosphatidylcholine (Type X-E), CHAPS, and pepstatin were
from Sigma. Leupeptin, aprotinin, and phenylmethylsulfonyl fluoride
were from Roche Applied Science. The pSK vector was from Strat-
agene (La Jolla, CA). The pVL1392 vector was from BD Pharmingen
(San Diego, CA). The BacVector 3000 baculoviral DNA was from Nova-
gen (Madison, WI). Sf9 (Spodoptera frugiperda) insect cells were ob-
tained from the Lineberger Cancer Center at the University of North
Carolina (Chapel Hill, NC). High five (Trichoplusia ni) insect cells were
provided by Dr. Thomas Kost of GlaxoSmithKline (Research Triangle
Park, NC). HPC4 antibody affinity resin was provided by Dr. Charles
Esmon (Oklahoma Medical Research Foundation, Oklahoma City, OK).
Expression and Purification of Recombinant Wild-type and Mutant
Carboxylases—The cDNA for human -glutamyl carboxylase (20),
cloned into the pSK vector, was modified by site-directed mutagenesis
to construct the W390A, L394R, Y395A, S398A, W399A, and H404A
mutants. All constructs contain the FLAG epitope (DYKDDDDK se-
quence) at their amino termini and the HPC4 tag containing the
EDQVDPRLIDGK sequence (21) at their carboxyl termini. The con-
structs were subcloned into the pVL1392 vector, and the proteins ex-
pressed in baculovirus-infected High Five cells (22). The protein was
purified using the HPC4 antibody affinity resin as described (12).
Determination of Active Enzyme Concentrations of Wild-type and
Mutant Carboxylases—Active enzyme concentrations of the wild-type
and mutant carboxylases were determined as described before by ti-
trating the protein sample with fluorescent-labeled consensus propep-
tide (23).
FLEEL Carboxylation Studies—Carboxylase activities of the wild-
type, W390A, L394R, Y395A, S398A, W399A, and H404A enzymes were
initially determined by measuring 14CO2 incorporation into the peptide
substrate FLEEL as described before (17). Reactions were performed at
20 °C in 25 mM MOPS, pH 7.4, 500 mM NaCl, 1 mM FLEEL, 4–8 M
ProFIX18, 0.16% phosphatidylcholine, 0.16% CHAPS, 222 M KH2 and
1.4 mM NaH14CO3 (10 Ci).
Subsequent kinetic studies of FLEEL carboxylation were performed
with the wild type, L394R, Y395A, and W399A enzymes by measuring
14CO2 incorporation at varying concentrations of FLEEL. KH2 was used
at 222 M except in W399A reactions, which contained 28 M KH2 for
reasons described below. In FLEEL carboxylation reactions, the free
factor IX propeptide was also included: 5 M in wild type and L394R
reactions, and 11 M and 28 M in Y395A and W399A reactions, re-
spectively. Reactions were performed for 30 min with the wild-type and
L394R enzymes. Due to their low activities, the reaction times were
extended to 1 h with the Y395A and W399A enzymes.
Inhibition of FLEEL Carboxylation by Boc-mEEV—The tripeptide
Boc-mEEV, a substrate analog in which the amino-terminal glutamic
acid is modified to (2S,4S)-4-methylglutamic acid, is a strong competi-
tive inhibitor of wild-type carboxylase for FLEEL carboxylation (18, 24).
We examined the effect of Boc-mEEV on the inhibition of FLEEL
carboxylation, for the wild-type and L394R, Y395A, and W399A mutant
enzymes. FLEEL concentrations of 0.8, 10, 12, and 16 mM were used in
the wild-type, L394R, Y395A, and W399A reactions, respectively. These
studies were performed in the presence of the factor IX propeptide. Data
were analyzed using a competitive inhibition model.
Kinetic Studies of FIXproGla Carboxylations—Reactions were per-
formed at 20 °C in 25 mM MOPS, pH 7.4, 500 mM NaCl, 0.16% phos-
phatidylcholine, 0.16% CHAPS, 1.4 mM NaH14CO3 (10 Ci), and vary-
ing concentrations of FIXproGla. KH2 was used at 222 M in wild-type,
L394R, and Y395A reactions, while 28 M KH2 was used in W399A
carboxylations. The reactions were performed for 1 h.
Effect of Free ProFIX19 Concentration on FLEEL Carboxylation Ac-
tivity—In these studies, the effect of varying concentrations of Pro-
FIX19 on carboxylation of FLEEL was measured. The reactions were
carried out as described above for FLEEL carboxylation, except that the
FLEEL concentration was kept constant and the propeptide concentra-
tion was varied. FLEEL concentrations of 1, 12, 24, and 32 mM were
used in wild-type, L394R, Y395A, and W399A reactions, respectively.
Inhibition of FIXproGla Carboxylation by Free Propeptide—The free
propeptide of vitamin K-dependent proteins is a competitive inhibitor
for carboxylation of propeptide-linked substrates (22, 25). We examined
the effect of ProFIX19 on the carboxylation of FIXproGla for wild-type,
L394R, and Y395A enzymes. We could not do this experiment with
W399A because of its low activity and high Km for FIXproGla. We used
0.5 M FIXproGla in wild-type and Y395A reactions and 4 M in L394R
reactions. Data were analyzed using a competitive inhibition model.
Concentration Dependence of Vitamin K Hydroquinone on Carboxyl-
ation—The effect of varying concentrations of KH2 on FIXproGla car-
boxylation for wild-type, L394R, Y395A, and W399A was examined.
The reactions were performed at fixed FIXproGla concentrations of 1.2
M in wild-type and Y395A reactions, and at 10 and 20 M in L394R and
W399A reactions, respectively. The reactions were performed for 30
min with wild type and L394R and for 1 h with Y395A and W399A
mutants, because of their low activities.
Vitamin K Epoxidase Activity Assay—Vitamin K epoxide formation
by wild-type, L394R, and Y395A enzymes during their FLEEL carbox-
ylation reactions was measured. FLEEL carboxylations in the presence
of free propeptide were performed as described above, except that
unlabeled NaHCO3 was used. FLEEL concentrations of 1, 12, and 28
mM were used in the wild-type, L394R, and Y395A reactions, respec-
tively. Vitamin K epoxide formation was quantified as described (26).
RESULTS
Carboxylation of FLEEL—We created 6 mutations within
the highly conserved region of the carboxylase molecule. Of
these, three had activity similar to that of wild type: the activ-
ities were 774  39 pmol of 14CO2/h/pmol enzyme for WT,
590  14 for W390A, 699  15 for S398A and 822  21 for
H404A. In contrast, the activities of L394R, Y395A, and W399A
were dramatically reduced and were too low to be measured
except in the presence of propeptide; therefore, we did all
further characterizations at saturating propeptide concentra-
tions. The Km values of L394R, Y395A, and W399A for FLEEL
were significantly higher, 12-, 27-, and 45-fold than wild type
(Table I). Furthermore, their kcat values were reduced (Table I).
The kcat values of Y395A and W399A, were only 1–2% of wild
type. The catalytic efficiencies, kcat/Km, were 24-fold lower for
L394R and 2000-fold lower for Y395A and W399A than WT
(Table I). Substrate inhibition with FLEEL has been widely
observed and occurs at about 9 mM with the wild-type enzyme.
We observed substrate inhibition at 18 mM for L394R (12).
However, consistent with their lower affinity for FLEEL, nei-
ther Y395A nor W399A exhibited substrate inhibition up to
FLEEL concentrations of 30 and 50 mM, respectively.
Inhibition of FLEEL Carboxylation by Boc-mEEV—The tri-
peptide Boc-mEEV was previously shown to be an active site-
specific, competitive inhibitor of FLEEL carboxylation (18, 24).
The Ki of Boc-mEEV for wild-type carboxylase was 0.013 
FIG. 1. Comparison of the amino acid sequences among sev-
eral species in a highly conserved region of -glutamyl carbox-
ylase between residues 374 and 405 (human sequence number-
ing). The region between residues 393 and 404 is identical among all
these species.
TABLE I
Comparison of the kinetic parameters of wild-type, L394R,
Y395A, and W399A carboxylases for FLEEL
Enzyme Km kcat kcat/Km
mM h1 h1 mM1
WT 0.54  0.10 763  139 1413
L394R 6.49  0.72 392  26 60
Y395A 14.8  3.6 6.8  0.4 0.46
W399A 24.3  0.8 11.7  0.2 0.48
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0.002 mM, in the range reported in previous studies. However,
Boc-mEEV is a significantly weaker inhibitor for FLEEL car-
boxylation for L394R, Y395A, and W399A (Fig. 2); Ki values of
1.4  0.2 mM and 2.1  0.3 mM were determined for L394R and
Y395A, respectively, while we could not determine the Ki for
W399A, but it was 5 mM.
Carboxylation of FIXproGla—The Km of substrates with a
propeptide is 1000-fold less than substrates lacking the propep-
tide (17, 27, 28). FIXproGla, a peptide substrate based on the
Gla domain of human factor IX covalently-linked to its propep-
tide, appears to mimic a physiological substrate of vitamin
K-dependent carboxylase (17, 25). While the kcat of Y395A for
FIXproGla is less than 10% of that of wild-type, its Km is
similar to that of the wild type (Table II). On the other hand,
L394R and W399A both have higher Km values for FIXproGla
than does wild type; 9-fold and 24-fold respectively. The kcat
values for FIXproGla carboxylation by Y395A and W399A were
only 7 and 11%, respectively, of that of wild type. In contrast,
the kcat for L394R is 2.7-fold higher than that for wild type,
which we discussed before (12). Compared with wild type, the
kcat/Km values for FIXproGla carboxylation are lower in the
mutants, the most prominent effect observed in W399A
(Table II).
Affinity of Wild-type, L394R, Y395A, and W399A Carboxy-
lases for ProFIX19—The free propeptides of vitamin K-depend-
ent coagulation proteins enhance the rate of carboxylation of
small glutamate peptide substrates (29, 30). Wild-type carbox-
ylase shows significant activity toward FLEEL carboxylation
even in the absence of propeptide. In the presence of saturating
propeptide, the rate of carboxylation by wild-type enzyme in-
creases 5–6-fold. Because of their low activity in the absence of
propeptide, it was difficult to estimate the fold increase with
propeptide for Y395A, W399A, and L394R, but the increases
were about 8-, 11-, and 100-fold, respectively. From the de-
pendence of FLEEL carboxylation activity on propeptide con-
centration (Fig. 3, A and B), the apparent affinities (Kd) of
wild-type, L394R, Y395A, and W399A carboxylases for Pro-
FIX19 were determined by assuming that the increase in ac-
tivity is proportional to the occupancy of the propeptide binding
site. The apparent Kd values of L394R, Y395A, and W399A
were 17-, 2-, and 23-fold higher than that of wild type respec-
tively (Table III).
Inhibition of FIXproGla Carboxylation by Free Propep-
tide—In a further comparison of the relative affinities of
wild-type, L394R, Y395A, and W399A, we measured the Ki
values of the factor IX propeptide as it competitively inhibits
carboxylation of FIXproGla (22, 25) (Fig. 4 and Table III). The
affinity of Y395A was similar to that of wild type. On the
other hand, the L394R affinity was about 7-fold lower than
that of wild type, and that of W399A could not be determined,
due to its high Km for FIXproGla and its low activity for
FIXproGla carboxylation. The relative affinities of wild type,
L394R, and Y395A for the propeptide determined by this
approach and the method examining the effect of propeptide
on stimulation of FLEEL carboxylation discussed above were
comparable (Table III).
Effect of Vitamin K Hydroquinone on Carboxylation—We
measured the dependence of FIXproGla carboxylation on KH2
FIG. 2. Inhibition of FLEEL carboxylation by the active site
specific inhibitor Boc-mEEV. The relative rates (Vi/V0) of FLEEL
carboxylation for the wild-type (), L394R (), Y395A (‚), and W399A
() enzymes are plotted versus the concentration of Boc-mEEV. V0 is
14CO2 incorporation in the absence of Boc-mEEV and Vi is CO2 incor-
poration at a given concentration of Boc-mEEV. The reactions were
performed in the presence of propeptide and 0.8, 10, 12, and 16 mM
FLEEL for the wild-type, L394R, Y395A, and W399A carboxylases,
respectively. The Ki values determined are 0.013  0.002 mM, 1.4  0.2
mM, and 2.1  0.3 mM for wild-type, L394R, and Y395A enzymes,
respectively. Ki for W399A carboxylase was estimated to be 5 mM.
TABLE II
Comparison of the kinetic parameters of wild-type, L394R, Y395A,
and W399A carboxylases for FIXproGla
Enzyme Km kcat kcat/Km
M h1 h1 mM1
WT 0.23  0.03 81  4 352,174
L394R 2.08  0.23 220  45 105,769
Y395A 0.20  0.04 6.0  1.2 30,000
W399A 5.53  0.57 8.8  1.4 1,591
FIG. 3. Stimulation of FLEEL carboxylation by ProFIX19. Car-
boxylation of FLEEL at different ProFIX19 concentrations is shown in
panel A for wild-type () and L394R () enzymes and in panel B for
Y395A (‚) and W399A () enzymes. The reactions were performed at 1,
12, 24, and 32 mM FLEEL for wild-type, L394R, Y395A, and W399A
enzymes, respectively. The apparent Kd of ProFIX19 for the wild-type,
L394R, Y395A, and W399A carboxylases are 24  2 nM, 412  33 nM,
50  6 nM, and 562  25 nM, respectively.
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concentration for wild type, L394R, Y395A, and W399A. Since
L394R and W399A have higher Km values for FIXproGla than
wild-type and Y395A (Table II), we used a higher FIXproGla
concentration in L394R and W399A reactions. The Km values
for KH2 were: 7.0  1.2 M, 32.8  5.4 M, and 38.5  9.6 M
for WT, L394R, and Y395A enzymes, respectively (Fig. 5, A and
B). The Km of W399A for KH2 could not be determined accu-
rately since higher KH2 concentrations inhibited its activity
(Fig. 5B); the Km was estimated to be about 10 M from the
initial phase of the kinetic curve. Therefore, all kinetic studies
of the W399A mutant were performed at 28 M KH2. The
reason for onset of inhibition at a lower KH2 concentration for
W399A is not clear, but similar phenomena have been reported
in some other carboxylase mutants (31). The rate of carboxyl-
ation measured at 28 M KH2 for W399A is about 70% of the
Vmax predicted from extrapolating the initial non-inhibitory
phase of the kinetic curve.
Vitamin K Epoxide Formation—Rates of vitamin K epoxide
(KO) formation were measured as 48.8  1.5, 27.6  0.4, and
9.8  0.1 pmol of KO/min/pmol of enzyme for wild type, L394R,
and Y395A. The amount of KO formed in W399A reactions was
too low to be quantitated precisely, due to the low KH2 concen-
tration (28 M) used in W399A reactions (see above). As was
observed with their reduced rates of carboxylation, L394R and
Y395A show reduced rates of epoxide formation relative to the
wild-type enzyme, suggesting that these mutant carboxylase
and epoxidase activities remain coupled (8, 32).
DISCUSSION
The objective of this study was to investigate the hypothesis
we suggested in our previous work (12), that the region around
amino acid 394 of human vitamin K-dependent carboxylase is
important for substrate binding. This mutation was found in
the carboxylase from an individual with combined deficiencies
of vitamin K-dependent proteins (9, 11). Leucine 394 is located
in a highly conserved region spanning residues 374–418 of the
human carboxylase. In this region of homology, identical se-
quences are present in human (20), bovine (33), mouse, rat (34),
and beluga whale (14) while 91% homology is observed with the
sequence of toadfish (14). In addition to the species listed
above, there are presently three known invertebrate carboxyl-
ase sequences: Drosophila (13, 15), Conus (14, 16) and Anoph-
eles. When the sequences of these invertebrate species are
added to the alignment, a smaller region, 390–404, of high
homology (only an asparagine changed to glutamine at 392 in
cone snail) is observed. This extreme sequence conservation
implies a structural and/or functional role for this region of the
carboxylase molecule.
To identify other potentially important residues in this re-
gion, we expressed and purified mutants W390A, Y395A,
S398A, W399A, and H404A, and examined their functional
properties. We recently developed a method for measuring the
active fraction of the carboxylase (23), so we also present here
the data for wild type and L394R corrected for active site
concentrations (12). Three of these five mutant enzymes,
W390A, S398A, and H404A, exhibited normal activity. To date,
TABLE III
Relative affinities of the factor IX propeptide for wild-type,





WT 24  2 63  13
L394R 412  33 459  28
Y395A 50  6 46  1
W399A 562  25 NDc
a Determined from ProFIX19 stimulation of FLEEL carboxylation.
b Determined from ProFIX19 inhibition of FIXproGla carboxylation.
c ND, not determined.
FIG. 4. Inhibition of FIXproGla carboxylation by ProFIX19.
The relative rates (Vi/V0) of FIXproGla carboxylation at varying Pro-
FIX19 concentrations are shown for the wild-type (), L394R (), and
Y395A (‚) enzymes. V0 is
14CO2 incorporation in the absence of Pro-
FIX19 and Vi is
14CO2 incorporation at a given concentration of Pro-
FIX19. The reactions were performed at 0.5 M FIXproGla for the
wild-type and Y395A enzymes, and at 4.0 M FIXproGla for the L394R
enzyme. The Ki values determined were 63  13 nM, 459  28 nM, and
46  1 nM for the wild-type, L394R, and Y395A carboxylases,
respectively.
FIG. 5. Carboxylation of FIXproGla at varying vitamin KH2
concentrations. The effect of vitamin KH2 concentration on FIXpro-
Gla carboxylation is shown in panel A for wild-type () and L394R ()
and in panel B for Y395A (‚) and W399A () enzymes. FIXproGla at 1.2
M were used in wild-type and Y395A reactions and at 10 and 20 M in
L394R and W399A reactions, respectively. The Km values of wild-type,
L394R, and Y395A for KH2 were determined as 7.0  1.2 M, 32.8  5.4
M, and 38.5  9.6 M, respectively. The W399A mutant is inhibited at
lower KH2 concentrations, as shown.
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only certain cysteine residues have been identified as part of
the carboxylase active site (35, 36). In addition to cysteines, the
participation of other amino acids in catalysis by a multisub-
strate enzyme, such as carboxylase, seems likely. We had hy-
pothesized that tryptophan, serine, and histidine were possible
candidates for catalytic or substrate binding residues. Indeed
Trp399 does appear to be important, but since changing these
other three residues has no obvious effect on activity or stabil-
ity, it is unlikely that they are important either for catalytic
function or for structural integrity. If important for maintain-
ing the enzyme structure, one would predict that changing a
bulky residue like tryptophan to alanine would create a cavity
making the enzyme less stable (37). Furthermore, the serine to
alanine mutation would remove a potential hydrogen bond to
devastating effect if structural, but the mutation has no effect
on stability or activity. Finally, the conserved histidine at po-
sition 404 in this region of substrate binding, a possible candi-
date for an active site residue, has no effect on the enzyme
activity.
On the other hand, the changes of Y395A and W399A, both
affected carboxylase activity. Like L394R, which we character-
ized earlier, these two mutants’ primary defect appears to be
substrate binding, specifically the region containing the glu
residues. L394R, Y395A, and W399A all have high Km values
for FLEEL relative to that of wild type. However, Km may or
may not be a good estimate for KS (substrate affinity). In the
simplest case, if kcat is small relative to the rate constant for
substrate dissociation (k1), then Km is similar to KS. So how do
we determine if kcat is small relative to k1? If kcat is large
relative to k1 then one can show that kcat/Km is an estimate of
the substrate association rate constant (k1). One would expect
k1 for a small molecule to be greater than 10
5 M1 s1, however,
for FLEEL carboxylation, kcat/Km is about 4  10
2 M1 s1 for
the wild-type enzyme and even lower for L394R, Y395A, and
W399A mutants. Therefore, kcat/Km is probably not close to k1.
We conclude that for FLEEL, kcat is small relative to k-1, and
therefore, Km is a reasonable estimate for KS. The weak inter-
actions of L394R, Y395A, and W399A with the glutamate sub-
strate are also reflected in the kcat/Km values for FLEEL car-
boxylation (Table I) which are 24-fold lower in L394R and
2,000-fold lower in Y395A and W399A, compared with wild
type.
The most convincing evidence that this region of the carbox-
ylase is part of a substrate-binding site is provided by inhibi-
tion studies of FLEEL carboxylation by the substrate analog,
Boc-mEEV. This active site-specific, competitive inhibitor of
FLEEL carboxylation (18, 24, 38) had Ki values for L394R,
Y395A and W399A 110- to 400-fold higher than for the wild-
type enzyme. Therefore, we conclude that the primary effect of
these mutations, as with L394R, is on substrate binding.
The effect on substrate binding may involve the carboxylat-
able glu residues and/or other substrate residues involved in
binding to carboxylase. The Leu394, Tyr395, and Trp399 residues
that play a role in substrate carboxylation, show hydrophobic
properties: the aromatic structure of tyrosine provides a certain
degree of hydrophobicity although its hydroxyl group has polar
characteristics. This observation may have some significance in
terms of understanding interactions between residues on the
enzyme and the substrate during binding events of the car-
boxylatable glutamates at the active site of carboxylase. Direct
interactions between these hydrophobic residues on carboxyl-
ase with substrate glutamates are unlikely, but they might
contact the methylene groups on the glutamates. Alternatively,
they may interact with hydrophobic amino acids on the sub-
strate that flank the carboxylatable glutamates. In this regard
it is interesting that peptides without a bulky hydrophobic
group preceding the glutamate residue are less active sub-
strates than those that do have such a group (39).
In parallel with their severely reduced activities for carbox-
ylation of FLEEL, Y395A, and W399A, have low kcat values for
carboxylation of the propeptide-linked substrate FIXproGla
(Table II). It should be noted that this is in contrast to L394R,
which has a high kcat for FIXproGla; moreover, while W399A
and L394R have higher Km values than wild type, the Km of
Y395A is similar to that of wild type. These results are harder
to interpret than those with FLEEL, since the kinetic constants
for FIXproGla are dependent on both the interaction of sub-
strate at the Glu binding site and at the propeptide site. In
addition there are multiple carboxylations (up to 12) for every
binding event. It appears that, for wild-type enzyme, the high
affinity of the propeptide for the enzyme results in the rate
limiting step being product release (40). A plausible explana-
tion of this is that the dissociation rate of a propeptide-contain-
ing substrate is slow relative to its rate of carboxylation.
FLEEL, on the other hand, is carboxylated and released with a
relatively fast dissociation rate, so carboxylation is probably
the rate-limiting step. We suggested in our L394R report that
that increased Vmax of the enzyme was due to its low affinity for
FIXproGla, which, in turn, is the result of the low affinity of the
enzyme, relative to wild type, for the propeptide. These effects
cause a faster release of product with L394R, and thus, a
higher Vmax. Like L394R, W399A has low affinity for the
propeptide, but its catalytic efficiency is low so the overall effect
on Vmax is negative. Y395A also has low catalytic efficiency, but
unlike the other two mutants, its affinity for propeptide is
similar to that of wild type. So for Y395A carboxylation is still
the rate-limiting step, and Vmax is reduced.
To further illustrate this point we offer a comparison of the
kcat values for FLEEL and FIXproGla (Table IV). The kcat of the
wild-type enzyme for FIXproGla is only 11% of that for FLEEL.
In contrast to the wild-type enzyme, Y395A, which has an
affinity for the propeptide similar to that of wild type, has a kcat
for FIXproGla 88% of that for FLEEL. This supports our inter-
pretation that, for Y395A, which has only 1% of the wild-type
enzyme’s activity for FLEEL, the glutamate carboxylation step,
rather than the product (propeptide) release step, is
rate-limiting.
L394R and W399A have reduced affinities for the factor IX
propeptide. As we suggested in our report on L394R, we believe
this is because of linkage between the glutamate and propep-
tide binding sites. These mutations do not disrupt linkage,
since all the enzymes respond to increasing concentrations of
propeptide with increased activity toward FLEEL. Perhaps the
most important observation in this regard is that Y395A binds
normally to the propeptide, while it, like L394R and W399A,
has reduced glutamate substrate binding. This result provides
further evidence that this region of the carboxylase is primarily
involved in the interaction with the Gla domain of the
substrate.
We and others have shown that vitamin K inhibits the car-
boxylase at high concentrations relative to Km for that sub-
strate (8). In addition, certain mutant enzymes are inhibited at
TABLE IV
Comparison of the ratio of FIXproGla to FLEEL carboxylation rates of






WT 81  4 763  139 0.11
L394R 220  45 392  26 0.56
Y395A 6.0  1.2 6.8  0.4 0.88
W399A 8.8  1.4 11.7  0.2 0.75
a kcat values expressed in h
1 units.
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lower vitamin K concentrations (31). W399A is inhibited at
lower vitamin K concentrations than either wild type or the
other mutants we have studied. We do not know why this is
true, but we postulate that one explanation is an ordered ad-
dition of substrates of the enzyme. The results from a previous
study point toward a mechanism with the ordered addition of
substrates to carboxylase: the exact order of binding, however,
could not be clearly shown (41). In addition, the finding that no
significant epoxide formation occurs in the absence of the glu-
tamate substrate (42), suggests it is possible that the gluta-
mate must bind to carboxylase before vitamin K for normal
function. This order may be reversed at high concentrations of
vitamin K, inhibiting the reaction. However, if enzyme affinity
for the glutamate substrate is lower than that of wild type, but
the affinity for vitamin K is normal, as is the case with W399A
(assuming Km is a measure of affinity), then inhibition may set
in at a lower vitamin K concentration. The L394R and Y395A
mutants, on the other hand, which have higher affinities for
glutamate than W399A, but appear to have lower affinities for
vitamin K, do not show inhibition at low vitamin K concentra-
tions. Confirmation of this hypothesis needs further study,
which is beyond the scope of this current work.
Others have reported various regions/residues in the carbox-
ylase molecule to be involved in interactions with the gluta-
mate substrate: a region in the amino terminus (43), regions
including the amino and carboxyl domains (44), residues
Lys218, Arg359, and His360 (31, 45), Cys343 and Tyr345 (46),
Cys99 and Cys450 (36). Of these residues proposed as functional
in substrate binding or activity, four, Cys343, Tyr345, Arg359,
and His360 are predicted to be located in the cytoplasm accord-
ing to the currently available topological study of the vitamin
K-dependent carboxylase (47). On the other hand, lysine 218,
and cysteines 99 and 450 are predicted to be in the lumen of the
endoplasmic reticulum where catalytic activity is expected to
reside (48). Since very little is known about the tertiary struc-
ture of the carboxylase, the proximity of these regions to the
region focused in our study is unknown. However, this con-
served region we have studied is located in the lumen of the
endoplasmic reticulum, as would be expected for the substrate
binding site(s).
In conclusion, our study has demonstrated that the con-
served sequence between residues 393–404 of human vitamin
K-dependent carboxylase defines an important region for inter-
actions with the glutamate substrate. In addition to playing a
major role in the binding of the glutamate substrate, some
residues in this region, but not all, appear to be involved in
linkage between the glutamate substrate binding site and
propeptide binding site of the enzyme.
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